Works citing this work

2 works

Work: Endogenous TCR promotes in vivo persistence of CD19-CAR-T cells compared to a CRISPR/Cas9-mediated TCR knockout CAR

1. Emerging strategies to reduce the side effects of CAR-T cell therapy: focusing on gene editing and nanotechnology

   Jinxin Dong, Denis Nikolenko, Shuxrat Boymuradov +2

   ArticleCAR-T cell therapy researchClinical & Translational Oncology20261 citations

   ABIABI:AkademIndex/openalex/2026.article.000172

2. Genetic engineering in oncology based on CRISPR-Cas9 technology

   D. Polatova, А. Yu. Madaminov, А. V. Savkin +1

   ArticleCRISPR and Genetic EngineeringSiberian Journal of Oncology20240 citations

   ABIABI:AkademIndex/openalex/2024.article.008036